🇺🇸 FDA
Patent

US 10711068

Anti-CD133 monoclonal antibodies and related compositions and methods

granted A61KA61K2039/505A61P

Quick answer

US patent 10711068 (Anti-CD133 monoclonal antibodies and related compositions and methods) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61P, A61P35/00